Oncology News | pharmaphorum

News

Ambros' $125m for pain disorder drug, and other financings

Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.

News

J&J's subcutaneous Rybrevant cleared by FDA

J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.

News

AstraZeneca and Daiichi Sankyo logos next to Datroway box

Datroway filed for TNBC in EU after data delay

Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.

News

MSD claims two national priority vouchers; report

The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.

News

As year-end nears, pharma groups plump up their pipelines

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

Editor's Picks